You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 6,872,739

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,872,739

Title:	Use of riluzole for the treatment of multiple sclerosis
Abstract:	Methods for the treatment of multiple sclerosis are disclosed comprising administering 6-(triflouromethoxy)-2-benzothiazolamine or a salt thereof.
Inventor(s):	Polman; Chris (Overveen, NL)
Assignee:	Vereniging Voor Christelijk Wetenshappelikjk Onderwijs (Amsterdam, NL)
Application Number:	09/926,693
Patent Claims:	1. A method for the treatment of multiple sclerosis, comprising administering to a patient in need of such treatment a pharmaceutical composition comprising a therapeutically effective amount of 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof. 2. The method of claim 1 wherein said pharmaceutical composition comprises a pharmaceutically effective carrier. 3. The method of claim 1 wherein said pharmaceutical composition further comprises a therapeutically or prophylactically effective amount of an additional agent. 4. The method of claim 3 wherein said additional agent is selected from the group consisting of interferon beta-1a, interferon beta-1b, and copaxone. 5. The method according to claim 1 wherein the amount of 6-(trifluoromethoxy)-2-benzothiazolamine or the salt thereof administered to the patient is between about 10 and about 500 mg per day. 6. The method of claim 5 wherein the amount of 6-(trifluoromethoxy)-2-benzothiazolamine or the salt thereof administered to the patient is between about 50 and about 250 mg per day. 7. The method of claim 1, wherein the composition comprises 6-(trifluoromethoxy)-2-benzothiazolamine. 8. The method of claim 1, wherein the composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine. 9. A method for treating a patient suffering from multiple sclerosis comprising the step of administering a pharmaceutical composition comprising 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof in an amount effective to inhibit, minimize or delay the development of spinal cord atrophy associated with multiple sclerosis. 10. The method of claim 9 wherein said pharmaceutical composition further comprises a therapeutically or prophylactically effective amount of an additional agent selected from the group consisting of interferon beta-1b, interferon beta-1a, and copaxone. 11. The method of claim 9, wherein the composition comprises 6-(trifluoromethoxy)-2-benzothiazolamine. 12. The method of claims 9, wherein the composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine. 13. A method for the treatment of a patient suffering from multiple sclerosis comprising the steps of administering to said patient: a. a therapeutically effective amount of a pharmaceutical composition comprising 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof; and b. a therapeutically effective amount of a pharmaceutical composition selected from the group consisting of interferon beta-1b, interferon beta-1a, and copaxone. 14. The method of claim 13, wherein the composition comprises 6-(trifluoromethoxy)-2-benzothiazolamine. 15. The method of claim 13, wherein the composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine. 16. A method for the treatment of a patient suffering from primary progressive multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof. 17. The method of claim 16 further comprising the administration of a therapeutically effective amount of interferon beta-1b, copaxone and interferon beta-1a. 18. The method of claim 16, wherein the composition comprises 6trifluoromethoxy)-2-benzothiazolamine. 19. The method of claim 16, wherein the composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine. 20. A method for the treatment of a patient suffering from secondary-progressive multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof. 21. The method of claim 20, wherein the composition comprises 6-(triflouromethoxy)-2-benzothiazolamine. 22. The method of claim 20, wherein the composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine. 23. A method for the treatment of a patient suffering from relapsing-remitting multiple sclerosis comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising 6-(trifluoromethoxy)-2-benzothiazolamine or a salt thereof. 24. The method of claim 23, wherein the composition comprises 6-(triflouromethoxy)-2-benzothiazolamine. 25. The method of claim 23, wherein the composition comprises a salt of 6-(trifluoromethoxy)-2-benzothiazolamine.

Details for Patent 6,872,739

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bayer Healthcare Pharmaceuticals Inc.	BETASERON	interferon beta-1b	For Injection	103471	07/23/1993	⤷ Try a Trial	2019-06-04
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996	⤷ Try a Trial	2019-06-04
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	05/28/2003	⤷ Try a Trial	2019-06-04
Biogen Inc.	AVONEX	interferon beta-1a	Injection	103628	02/27/2012	⤷ Try a Trial	2019-06-04
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	03/07/2002	⤷ Try a Trial	2019-06-04
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/17/2004	⤷ Try a Trial	2019-06-04
Emd Serono, Inc.	REBIF	interferon beta-1a	Injection	103780	12/21/2012	⤷ Try a Trial	2019-06-04
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.